The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Abstract
The search for novel drugs for treating psychiatric disorders is driven by the growing medical need to improve on the effectiveness and side-effect profile of currently available therapies. Given the wealth of preclinical data supporting the role of neuropeptides in modulating behaviour, pharmaceutical companies have been attempting to target neuropeptide receptors for over two decades. However, clinical studies with synthetic neuropeptide ligands have been unable to confirm the promise predicted by studies in animal models. Here, we analyse preclinical and clinical results for neuropeptide receptor ligands that have been studied in clinical trials for psychiatric diseases, including agents that target the receptors for tachykinins, corticotropin-releasing factor, vasopressin and neurotensin, and suggest new ways to exploit the full potential of these candidate drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, no clinical studies to date have found efficacy of CRF 1 receptor antagonists for the treatment of other stress-related psychiatric disorders, such as major depression, generalized anxiety disorder, social anxiety, or posttraumatic stress disorder (Griebel and Holsboer, 2012;Dunlop et al., 2017).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Griebel and Holsboer, 2012
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Self-citationVale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Hammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Self-citationAnimal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Hökfelt, T. G. M., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,552
Flagged first, then by citations
Research works printed but not linked: 6
- Chappell, P. Effect of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. In: Proceedings of the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2002).
- Ratti, E. et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727–733 (2011). · DOI
- Liebowitz, M., Sheehan, D., Melia, L. A. & Siffert, J. Safety and efficacy of AV608 in subjects with social anxiety disorder. In: Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2007).
- Wernet, W. et al. In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Program No. 560.16. 2008 Neuroscience Meeting Planner (Washington DC; Society for Neuroscience; 2008).
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). (American Psychiatric Association, Washington DC, 2000).
- Kirsch, I. The Emperor's New Drugs: Exploring the Antidepressant Myth (Bodley Head, 2010).
Cited by
Sorted by citations
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Structure of the agonist-bound neurotensin receptor
White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 527
Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement
Koob, G. F. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.023 · Cited by 477
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Detecting Activated Cell Populations Using Single-Cell RNA-Seq
Wu, Y. E., Pan, L., Zuo, Y., Li, X., & Hong, W. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.026 · Cited by 438
Metadata
- Authors
- Griebel, G., & Holsboer, F.
- Affiliations
- Sanofi (France) (FR)
- Max Planck Institute of Psychiatry (DE)
- Corresponding author
- Griebel, Guy
- ORCID
- Griebel, Guy
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-05-18
- Volume
- 11
- Issue
- 6
- Pages
- 462-478
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2089617519
- Cited by
- 194
- References
- 176
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 20 · 2015: 22 · 2014: 19 · 2013: 23 · 2012: 9
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- psychiatric drug development, tachykinins, corticotropin-releasing factor, vasopressin, neurotensin, clinical translation, adverse effects
- MeSH terms
- Animals, Mental Disorders, Corticotropin-Releasing Hormone, Humans, Ligands, Neurotensin, Psychotropic Drugs, Vasopressins, Tachykinins, Drug Delivery Systems, Receptors, Vasopressin, Receptors, Neuropeptide, Receptors, Corticotropin-Releasing Hormone, Receptors, Neurotensin, Receptors, Tachykinin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
